What’s the combined value of Tylenol, Neutrogena, Listerine, Band-Aid, Aveeno, Zyrtec—plus a few more of the biggest names in consumer health? On Monday afternoon,

Johnson & Johnson


which owns each of these brands, put a number on it: About $40 billion.

That valuation comes as

Johnson & Johnson


(ticker: JNJ) begins the long-awaited spinoff of its consumer health division under the name Kenvue. The first step is an initial public offering, which could take place in the coming week. Johnson & Johnson is pricing the IPO at between $20 and $23 per share, and expects to raise about $3.2 billion.



Source link

Previous articleSerta Princeton Modern Futon only $197 shipped (Reg. $500!)
Next articleTerminusCode | Software, Service, Provider, Installer

LEAVE A REPLY

Please enter your comment!
Please enter your name here